| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 524.29M | 541.74M | 499.96M | 423.50M | 387.51M | 304.58M |
| Gross Profit | 248.99M | 9.87M | 337.57M | 368.11M | 320.30M | 266.47M |
| EBITDA | -32.98M | -28.60M | 41.85M | 66.06M | 58.91M | 39.31M |
| Net Income | -91.94M | -89.09M | -6.53M | 25.39M | 31.08M | 22.05M |
Balance Sheet | ||||||
| Total Assets | 0.00 | 821.55M | 774.23M | 652.07M | 640.54M | 463.71M |
| Cash, Cash Equivalents and Short-Term Investments | 46.49M | 40.70M | 16.88M | 13.41M | 8.29M | 43.35M |
| Total Debt | 0.00 | 347.28M | 259.13M | 167.15M | 184.96M | 116.99M |
| Total Liabilities | -315.85M | 505.70M | 376.61M | 251.09M | 265.52M | 163.43M |
| Stockholders Equity | 315.85M | 315.13M | 397.20M | 400.99M | 375.02M | 300.28M |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -69.53M | -72.06M | 9.40M | -36.00M | 53.55M |
| Operating Cash Flow | 0.00 | -24.71M | 27.63M | 73.53M | -4.40M | 58.64M |
| Investing Cash Flow | 0.00 | -63.44M | -100.69M | -57.18M | -27.17M | -283.29K |
| Financing Cash Flow | 0.00 | 87.50M | 67.76M | -33.29M | 9.55M | -36.86M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | ₹5.71B | 27.54 | ― | 0.84% | 6.66% | -21.40% | |
55 Neutral | $13.29B | 17.42 | 10.03% | 0.93% | 7.13% | -12.93% | |
53 Neutral | ₹3.91B | 27.91 | ― | ― | 17.09% | ― | |
41 Neutral | ₹941.48M | -10.25 | ― | ― | -4.57% | 23.01% | |
40 Underperform | ₹3.93B | ― | ― | ― | -6.13% | 98.35% |
Banka BioLoo Limited has announced the publication of its unaudited financial results for the quarter and half-year ending September 30, 2025. These results have been published in the ‘Financial Express’ and ‘Nava Telangana’ newspapers, adhering to the regulatory requirements of the Securities and Exchange Board of India. This timely disclosure underscores the company’s commitment to transparency and regulatory compliance, potentially impacting investor confidence and market positioning.
Banka BioLoo Limited conducted its 13th Annual General Meeting (AGM) on September 10, 2025, via video conferencing. The meeting included the presence of key directors and auditors, with 38 members participating. The AGM proceedings were in compliance with regulatory requirements, and the company announced that the voting results would be disclosed within two working days. This meeting underscores the company’s commitment to transparency and regulatory adherence, potentially strengthening its position in the sanitation industry.